Rand, Patricia J.; Schooff, Michael
November 1999
Journal of Family Practice;Nov1999, Vol. 48 Issue 11, p847
Academic Journal
The article investigates independent and combined effects of n-3 polyunsaturated fatty acids and vitamin E on morbidity and mortality after myocardial infarction (MI). The study enrolled a total of 11, 324 Italian patients who experienced an MI within the previous three months. Cumulative rate of all-cause death, nonfatal MI and nonfatal stroke are the primary outcomes that were assessed in the study. For those receiving vitamin E supplementation, no reductions in mortality or cardiovascular events were found.


Related Articles

  • Daily omega-3 reduces chance of fatal CVD event.  // GP: General Practitioner;9/5/2008, p4 

    The article reports on the result of the study which examines the beneficial effects of a daily dose of omega-3 fatty acids conducted in Italy. The study shows that a daily dose of omega-3 fatty acids could help to reduce the risk of cardiovascular events in patients who already have chronic...

  • Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation. Nodari, Savina; Triggiani, Marco; Campia, Umberto; Dei Cas, Livio // JAFIB: Journal of Atrial Fibrillation;Dec2012/Jan2013, Vol. 5 Issue 4, p49 

    Atrial fibrillation (AF) is the most prevalent arrhythmia and is associated with considerable morbidity and mortality. Available pharmacologic antiarrhythmic therapies are often ineffective in preventing the recurrence of AF, possibly because these drugs target a single pathophysiological...

  • Effect of N-33 Polyunsaturated Fatty Acids in Heart Failure. Crawford, Michael H. // Clinical Cardiology Alert;Dec2008, Vol. 27 Issue 12, p94 

    The article presents a study about the effect of n-3 polyunsaturated fatty acids (PUFA) in patient with heart failure. It notes that a lower mortality rate in post myocardial infarction patients who were treated with n-3 PUFA is demonstrated in this study. It states that in this study, the...

  • Editorials: Vitamin E and Cardiovascular Disease: A Genetic Factor. Gaby, Alan R. // Townsend Letter;Apr2008, Issue 297, p140 

    The author reflects on the benefits offered by vitamin E to patients with cardiovascular diseases. He cites that the Cambridge Heart Antioxidant Study shows that supplementation with 400 to 800 international units (IU)/day of vitamin E resulted in reduction of myocardial infarction incidence of...

  • REVIEW Effect of Supplemental Vitamin E for the Prevention and Treatment of Cardiovascular Disease. Shekelle, Paul G.; Morton, Sally C.; Jungvig, Lara K.; Udani, Jay; Spar, Myles; Tu, Wenli; Suttorp, Marika J.; Coulter, Ian; Newberry, Sydne J.; Hardy, Mary // JGIM: Journal of General Internal Medicine;Apr2004, Vol. 19 Issue 4, p380 

    To evaluate and synthesize the evidence on the effect of supplements of vitamin E on the prevention and treatment of cardiovascular disease. Systematic review of placebo-controlled randomized controlled trials; meta-analysis where justified. Eighty-four eligible trials were identified. For the...

  • Independent Nurse: Celecoxib as likely to cause MI as rofecoxib.  // GP: General Practitioner;3/10/2006, p84 

    This article reports on a meta-analysis of four studies, which found that the COX-2 inhibitor celecoxib increases the risk of myocardial infarction (MI) as much as the withdrawn drug rofecoxib. The analysis compared the risk of MI, cardiovascular events, cardiovascular deaths and stroke in 4,422...

  • The Effect of Fine and Coarse Particulate Air Pollution on Mortality: A National Analysis. Zanobetti, Antonella; Schwartz, Joel // Environmental Health Perspectives;Jun2009, Vol. 117 Issue 6, p898 

    BACKGROUND: Although many studies have examined the effects of air pollution on mortality, data limitations have resulted in fewer studies of both particulate matter with an aerodynamic diameter of = 2.5 μm (PM2.5; fine particles) and of coarse particles (particles with an aerodynamic...

  • Risk factors for cerebrovascular and cardiovascular diseases beyond age 75 years. Mostafaie, N.; Huber, K.; Sebesta, C.; Krampla, W.; Jungwirth, S.; Zehetmayer, S.; Hinterberger, M.; Krugluger, W.; Tragl, K.; Fischer, P. // Journal of Neural Transmission;Nov2010, Vol. 117 Issue 11, p1247 

    Globally, cardiovascular diseases (CVDs) are the number one cause of all mortalities. Of these deaths, 7.6 million are due to heart attacks, and 5.7 millions are due to stroke. The Vienna Transdanube Aging Study (VITA), a population-based cohort study, enabled us to evaluate associations between...

  • Reduction of Iron Stores and Cardiovascular Outcomes in Patients With Peripheral Arterial Disease. Zacharski, Leo R.; Chow, Bruce K.; Howes, Paula S.; Shamayeva, Galina; Baron, John A.; Dalman, Ronald L.; Malenka, David J.; Ozaki, C. Keith; Lavori, Philip W. // JAMA: Journal of the American Medical Association;2/14/2007, Vol. 297 Issue 6, p603 

    The authors present the results of their randomized controlled trial to determine whether reducing stores of iron in the body through phlebotomy would have any effect on clinical outcomes in a group of patients with symptomatic peripheral arterial disease. Accumulation of excess iron has been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics